Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabin-strain inactivated poliovirus vaccine + hepatitis A inactivated vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Sabin-strain inactivated poliovirus vaccine (sIPV) and hepatitis A inactivated vaccine (HepA) combination is a multivalent vaccine candidate designed to provide simultaneous protection against poliomyelitis and hepatitis A. The sIPV component utilizes attenuated Sabin strains (Types 1, 2, and 3) rather than the wild-type strains used in traditional Salk IPV, which enhances biosafety during the manufacturing process by reducing the risk of environmental reintroduction of virulent poliovirus. The hepatitis A component consists of inactivated hepatitis A virus (HAV), typically cultured in human diploid cells. This combination vaccine aims to simplify pediatric immunization schedules and improve compliance by reducing the number of required injections. Major development programs for this combination are led by Chinese biopharmaceutical companies, including Sinovac Biotech and Beijing Minhai Biotechnology (a subsidiary of Kangtai Biological), with clinical trials demonstrating immunogenicity and safety profiles comparable to the individual vaccines.
- Other names
- sIPV-HepA vaccineSabin-strain Inactivated Poliovirus and Hepatitis A Combined Vaccine
Beyond the preview
Go deeper on sabin-strain inactivated poliovirus vaccine + hepatitis A inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine + hepatitis A inactivated vaccine.